Cumulus Oncology is developing anti‑cancer therapies for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients. In particular, the company is interested in the identification of specific molecular targets and biomarkers associated with ferroptosis, which allow for the development of targeted therapies.
Approaches of Interest:
- All cancers are within scope
- Open to different modalities including small molecules, biologics and mRNA therapeutics, targeting any mechanism of ferroptosis
- Platforms that ...